0H7R Stock Chart & Stats
$6.33
$0.26(4.11%)
At close: 4:00 PM EDT
$6.33
$0.26(4.11%)
Day’s Range― - ―
52-Week Range$3.84 - $8.25
Previous CloseN/A
Volume3.00K
Average Volume (3M)7.86K
Market Cap
$343.68M
Enterprise Value$225.61
Total Cash (Recent Filing)$146.83M
Total Debt (Recent Filing)$19.87M
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Nov 16, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.14
Shares Outstanding57,184,017
10 Day Avg. Volume9,506
30 Day Avg. Volume7,855
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.75
Price to Sales (P/S)47.95
P/FCF Ratio-3.31
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$20.50Price Target Upside223.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.95
Revenue Forecast (FY)$54.61M
Bulls Say, Bears Say
Bulls Say
Commercial Revenue GrowthEarly revenue growth indicates increasing adoption of ZEVASKYN after launch. Continued treatment activity and physician engagement could establish a durable commercial base as more centers reach steady-state operations.
Market Access And ReimbursementExpansion of qualified treatment centers improves patient access, while NTAP provides supplemental hospital reimbursement. Together, these structural developments can reduce adoption friction and support broader uptake of the therapy.
Financial FlexibilityA substantial liquidity position and modest leverage provide flexibility to fund commercialization and development. This gives Abeona more time to address execution issues and pursue growth before requiring additional capital.
Bears Say
Persistent Losses And Cash BurnLarge recurring losses and negative cash generation indicate that current revenue does not yet support the cost base. Unless profitability improves, Abeona may remain dependent on external financing, creating dilution and execution risk.
Manufacturing Yield RiskManufacturing failures directly reduce billable treatments while leaving the company with production costs. Recurrence could constrain revenue growth, weaken margins and undermine confidence in the reliability of the commercial supply process.
Operational And Regulatory ComplexityThe therapy requires tightly coordinated logistics and specialized sites, while assay-specification discussions add regulatory uncertainty. These constraints can delay treatments, make revenue timing unpredictable and slow the pace of market expansion.
Abeona Therapeutics News
0H7R FAQ
What was Abeona Therapeutics’s price range in the past 12 months?
Abeona Therapeutics lowest share price was $3.84 and its highest was $8.25 in the past 12 months.
What is Abeona Therapeutics’s market cap?
Abeona Therapeutics’s market cap is $343.68M.
When is Abeona Therapeutics’s upcoming earnings report date?
Abeona Therapeutics’s upcoming earnings report date is Nov 16, 2026 which is in 79 days.
How were Abeona Therapeutics’s earnings last quarter?
Abeona Therapeutics released its earnings results on Aug 13, 2026. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.232 by -$0.118.
Is Abeona Therapeutics overvalued?
According to Wall Street analysts Abeona Therapeutics’s price is currently Undervalued.
Does Abeona Therapeutics pay dividends?
Abeona Therapeutics pays a Notavailable dividend of $0.285 which represents an annual dividend yield of N/A. See more information on Abeona Therapeutics dividends here
What is Abeona Therapeutics’s EPS estimate?
Abeona Therapeutics’s EPS estimate is -0.16.
How many shares outstanding does Abeona Therapeutics have?
Abeona Therapeutics has 57,184,017 shares outstanding.
What happened to Abeona Therapeutics’s price movement after its last earnings report?
Abeona Therapeutics reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.232. Following the earnings report the stock price went down -13.76%.
Which hedge fund is a major shareholder of Abeona Therapeutics?
Currently, no hedge funds are holding shares in GB:0H7R
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Abeona Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.50 (223.85% Upside)
$20.50 (223.85% Upside)
Blogger Sentiment
Bullish
GB:0H7R Sentiment 91%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.12%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-27.10%
Trailing 12-Months
Company Description
Abeona Therapeutics
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
0H7R Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlights clear commercial progress: 31% quarter-over-quarter revenue growth, expansion to 7 QTCs, 12 patients treated since launch, improved average manufacturing yields in commercial runs, a strong balance sheet ($146.8M) and a significant NTAP reimbursement win that validates the therapy. However, material operational and manufacturing challenges (one low-yield and one out-of-spec batch causing unrevenueed treatments), logistical fragility around the 84-hour shelf life, regulatory work to revisit an assay specification, and continued GAAP losses introduce meaningful near-term execution risk and revenue volatility. Management has implemented clearer reporting metrics and is pursuing operational learnings to mitigate these issues, but variability in site activation and sensitivity to manufacturing yield remain key risks to the revenue ramp.View all GB:0H7R earnings summaries0H7R Stock 12 Month Forecast
Average Price Target
$20.50
▲(223.85% Upside)